{"id":"W2946889769","doi":"10.1200/jco.2019.37.15_suppl.1040","title":"Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with <i>PIK3CA-</i>mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Letrozole; Breast cancer; Oncology; Cohort; Regimen; Palbociclib; Cancer; Metastatic breast cancer; Estrogen receptor; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001547628,0.0006155806,0.00313164,0.0003468709,0.00009854123,0.0000250882,0.0004596444,0.0003260795,0.0004435975],"category_scores_gemma":[0.0009029121,0.0004241827,0.0004183706,0.0005535154,0.0004780933,0.0007811596,0.0001451811,0.002409792,0.00002742538],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001143146,"about_ca_system_score_gemma":0.00105779,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006562013,"about_ca_topic_score_gemma":0.0009101126,"domain_scores_codex":[0.9924984,0.001240457,0.003806134,0.0007897616,0.0009421961,0.0007230375],"domain_scores_gemma":[0.9908598,0.00239804,0.003733873,0.0004679622,0.002011685,0.0005286314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2272466,0.01644384,0.6109777,0.00003492229,0.002235649,0.0006085907,0.004483606,0.0003113777,0.001173572,0.0000274503,0.0004872954,0.1359694],"study_design_scores_gemma":[0.1094735,0.06112432,0.8236007,0.0004545642,0.0001331566,0.0001445222,0.001284259,0.00001183961,0.0005011592,0.00007265902,0.002812332,0.0003869454],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896103,0.00035186,0.00004437201,0.00565608,0.0008523542,0.001935144,0.0002160664,0.00003913717,0.001294687],"genre_scores_gemma":[0.9939159,0.001059288,0.001406249,0.002657256,0.0005437003,0.00005930462,0.00003947433,0.0001077748,0.0002110573],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.212623,"threshold_uncertainty_score":0.9998917,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04594670903478027,"score_gpt":0.4199377363683728,"score_spread":0.3739910273335925,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}